Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 8, 2014, Pages 739-747

  Seino, Y ^a   Takami, A ^b   Boka, G ^c   Niemoeller, E ^d   Raccah, D ^e   D'Emden, Michael ^f   Lowy, Andrew ^f   Forst, Thomas ^f   Hanefeld, Markolf ^f   Wagner, Frank ^f   Fuyuko, Kensuke ^f   Hayakawa, Hiroshi ^f   Imamura, Akira ^f   Kanada, Shigeto ^f   Jinnouchi, Hideaki ^f   Kasahara, Hirose ^f   Kawa, Ikkyou ^f   Maeda, Shuichi ^f   Matsubayashi, Sunao ^f   Morita, Hiroshi ^f   Nagashima, Hirotaka ^f   Nakano, Keiko ^f   Onde, Hajime ^f   Saito, Yamito ^f   Satake, Kazuo ^f   Shoji, Shigeichi ^f   Toh, Yasuo ^f   Tokoo, Masuo ^f   Wakida, Yasuchi ^f   Yano, Shintaro ^f   Yoshida, Hitoshi ^f   Burger, Francois ^f   Ellis, Graham ^f   Malan, Jacques ^f   Bak, Annette ^f   Reintke, Hendrik ^f   Rongen, Gerard ^f   more..

^a KANSAI ELECTRIC POWER CO   (Japan)

^b Sanofi KK ^*  (Japan)

^c SANOFI   (France)

^d Process Development Biotechnology   (Germany)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f NONE

Author keywords

Caucasian; Japanese; Lixisenatide; Prandial; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; INCRETIN; PEPTIDE; ZP10A PEPTIDE;

ADULT; AGED; ALLERGIC RHINITIS; APPLICATION SITE ERYTHEMA; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEAL; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARALLEL DESIGN; PHARMACODYNAMICS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; AGONISTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG MONITORING; JAPAN; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 84904396437     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12276     Document Type: Article

References (33)

1. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl. 1): S37-S43.
2. Iwahashi H, Okauchi O, Ryo M et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Investig 2012; 3: 271-275.
3. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-2178.
4. Cho YS, Chen CH, Hu C et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 2012; 44: 67-72.
5. Yasuda K, Miyake K, Horikawa Y et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40: 1092-1097.
6. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-716.
7. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010; 1: 8-23.
8. Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond the pancreas. J Diabetes Investig 2013; 4: 108-130.
9. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 737-745.
10. Lee S, Yabe D, Seino Y, Hirano T. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. J Diabetes Investig 2010; 1: 73.
11. Yabe D, Kuroe A, Watanabe K et al. Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls. J Diabetes Investig 2010; 1: 56-59.
12. Yabe D, Watanabe K, Sugawara K et al. Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig 2012; 3: 70-79.
13. Garber AJ, Abrahamson MJ, Barzilay JI et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract 2013; 19: 536-557.
14. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
15. Kohro T, Yamazaki T, Sato H et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 2013; 54: 93-97.
16. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010; 164: 58-64.
17. Gao Y, Yoon KH, Chuang LM et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
18. Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig 2011; 2: 448-456.
19. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
20. Kadowaki T, Namba M, Imaoka T. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Investig 2011; 2: 210-217.
21. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 341-347.
22. Kaku K, Rasmussen MF, Nishida T, Seino Y. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Investig 2011; 2: 441-447.
23. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 81: 161-168.
24. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.
25. Seino Y, Rasmussen MF, Nishida T, Kaku K. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011; 2: 280-286.
26. Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012; 14: 910-917.
27. Yang W, Chen L, Ji Q et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011; 13: 81-88.
28. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: S37.
29. Saloranta C, Guitard C, Pecher E et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25: 2141-2146.
30. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008; 31: 2086-2091.
31. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010; 27: 1024-1032.
32. Fonseca VA, Alvarado-Ruiz R, Raccah D et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35: 1225-1231.
33. Ratner RE, Hanefeld M, Shamanna P, Min K, Boka G, Miossec P, Muehlen-Bartmer I, Rosenstock J. Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea +/- metformin (GetGoal-S). EASD Annual Meeting, 12-16 September 2011, Lisbon, Portugal.